1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Beijing Aosaikang Pharmaceutical Co., Ltd. Class A

Beijing Aosaikang Pharmaceutical Co., Ltd. Class A

SSZSE:002755
12.10
CNY
+0.31
(+2.63%)
0.25EPS
53.00P/E
12.64BMarket Cap
Oct 29Next Earn
Beijing Aosaikang Pharmaceutical Co., Ltd. Class A
SZSE:002755
(Shenzhen Stock Exchange)

Recent

price

12.10

P/E

ratio

53.00

div

yld

0.74%

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
4.12
3.83
3.87
3.62
1.82
1.14
4.48
5.22
4.86
4.09
3.35
1.99
1.55
1.89
1.88
1.84
Revenue per Share
0.38
0.46
0.43
0.29
0.12
0.03
0.8
0.89
0.84
0.78
0.41
-0.24
-0.16
0.17
0.25
0.26
Basic EPS, GAAP
- -
0.79
-0.12
-0.29
-0.02
0.08
0.78
0.53
0.39
0.41
0.47
-0.22
-0.17
0.19
0.54
- -
Free Cash Flow per Basic Share
0.06
0.09
0.09
0.09
0.05
0.02
1.39
- -
0.13
0.22
0.2
0.1
- -
- -
0.12
0.09
Dividend per Share
1.66
2.04
2.38
2.58
2.95
2.96
7.2
10.71
2.71
3.26
3.47
3.19
3.12
3.3
3.46
3.47
Book Value per Share
1.65
2.03
2.37
2.58
2.93
2.93
6.69
10.22
2.53
2.92
3.03
2.64
2.45
2.44
2.43
2.31
Tangible Book Value per Share
129
129
129
130
153
157
759
753
930
925
927
941
928
943
946
931
Basic Weighted Avg Shares
529
494
500
471
278
178
3,405
3,932
4,519
3,783
3,107
1,873
1,443
1,778
1,779
1,715
Sales/Revenue/Turnover
12.21
15.83
14.27
14.25
12.21
-3.29
19.62
18.44
19.04
19.83
11.45
-15.08
-17.89
6.64
13.31
14.96
Operating Margin (%)
- -
4
4
4
4
4
72
83
88
93
95
92
85
88
129
- -
Depreciation Expense
49
60
56
38
19
5
608
670
781
722
380
-226
-149
160
237
239
Net Income, GAAP
14.99
15.88
15.43
16.58
18.04
0.87
13.16
11.4
12.17
11.67
6.28
- -
- -
15.18
15.56
17.42
Effective Tax Rate (%)
9.29
12.13
11.09
7.96
6.78
2.58
17.84
17.04
17.28
19.08
12.23
-12.06
-10.29
9.02
13.3
13.95
Profit Margin (%)
169
252
261
286
458
457
424
1,040
1,556
1,954
2,085
1,814
1,755
1,747
1,824
1,758
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
14
12
9
7
7
4
4
LT Debt
215
263
308
334
508
509
1,242
1,848
2,517
3,033
3,228
3,013
3,011
3,142
3,274
3,296
Total Equity
- -
23.36
19.17
12.37
4.83
0.29
71.05
42.81
34.88
24.68
11.79
- -
- -
4.18
6.55
7.17
Return on Invested Capital (%)
- -
25.07
19.45
11.58
4.26
0.25
68.74
43.15
35.81
25.8
12.14
- -
- -
6.12
7.98
7.4
Return on Capital (%)
- -
25.07
19.45
11.7
4.48
0.9
69.47
43.45
35.84
26.05
12.17
-7.31
-5.07
5.38
7.54
7.51
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
30
3
3
LT Borrowings
- -
- -
- -
LT Finance Leases
4
3
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
928
928
928
Market Capitalization
15,157
14,535
12,642

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,991
2,921
2,765
Cash, Cash Equivalents & STI
2,481
2,481
2,335
Accounts Receivable, Net
205
140
225
Inventories
125
118
121
Total Current Liabilities
1,167
1,069
1,007
Payables & Accruals
- -
- -
- -
ST Debt
30
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
25.78%
1.65%
4.2%
Free Cash Flow
385.98%
-38.29%
180.79%
Net Income, GAAP
1,263.63%
-80.27%
47.6%
Sales/Revenue/Turnover
173%
-11.46%
0.08%
Total Cash Common Dividend
6,270.25%
1,874.27%
9,526.49%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
448
474
462
393
1,778
2025
509
499
- -
345
1,779
2026
482
389
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.05
0.06
0.04
0.17
2025
0.06
0.11
- -
0.01
0.25
2026
0.09
0.04
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
0.09
- -
- -
0.12
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ) researches, develops, manufactures, markets and sells pharmaceuticals, fine chemicals and health-care products primarily in oncology, gastroenterology, antibiotic and anti-infective therapeutic areas in China. The company offers proton pump inhibitor injections including omeprazole sodium for injection, dexlansoprazole for injection, esomeprazole sodium for injection, lansoprazole for injection and rabeprazole sodium for injection; oncology medicines such as liotinib tablets, trifluoruridine tipipyrimidine tablets, neratinib maleate tablets, temozolomide capsules, lenvatinib mesylate capsules, decitabine for injection and dexrazoxane for injection; anti-infectives including polymyxin E sodium mesylate for injection, voriconazole for injection and daptomycin for injection; and other products like saxagliptin tablets and parecoxib sodium for injection. Through its subsidiary Jiangsu Aosaikang Pharmaceutical Co., Ltd., it produces proton pump inhibitors and operates from headquarters in Nanjing, China, where the company was founded in 2003. Recent developments include an exclusive license agreement with Shield Therapeutics for the development and commercialization of ACCRUFeR/Feraccru in China, Hong Kong, Macau and Taiwan; participation in innovation-driven M&A and licensing partnerships as part of Chinese pharma's embrace of European technologies; clinical trial approvals for ASKC202 and ASK120067 tablets combination for non-small cell lung cancer; and revenue growth in anti-infectives and chronic disease products exceeding 50% year-on-year in 2024.